Novo Nordisk A S SEC filings NVO

Novo Nordisk A S has 1,001 filings in SEC EDGAR's recent list, going back to Apr 1, 2016. Its latest annual report, Form 20-F, was filed on Feb 4, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.

Novo Nordisk A S SEC filings
Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Jun 22, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 10, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Mar 4, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Oct 21, 2025 —
144 Notice of proposed sale May 30, 2025 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Apr 23, 2025 —
SC 13G/A Amended ownership over 5% (passive) Feb 6, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 23, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 1, 2022 —
SC 13G/A Amended ownership over 5% (passive) Jan 29, 2021 —
SC 13G/A Amended ownership over 5% (passive) Feb 5, 2020 —
SC 13G Ownership over 5% (passive) Feb 3, 2020 —
SC 13G/A Amended ownership over 5% (passive) Feb 6, 2019 —
SC 13G/A Amended ownership over 5% (passive) Jan 25, 2019 —
SC 13G Ownership over 5% (passive) Dec 21, 2018 —
SC 13G/A Amended ownership over 5% (passive) Feb 8, 2018 —
SC 13G Ownership over 5% (passive) Feb 1, 2018 —
SC 13G/A Amended ownership over 5% (passive) Jan 25, 2017 —
SC 13G/A Amended ownership over 5% (passive) Sep 9, 2016 —
SC 13G/A Amended ownership over 5% (passive) Jun 16, 2016 —

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NVO (NYSE), NONOF (OTC)
Fiscal year ends
December 31
Headquarters
Bagsvaerd Denmark, Denmark
SEC filer status
Large accelerated filer
SEC CIK
353278

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.